Introduction
Parkinson's disease (PD) is an age-related progressive neurodegenerative disease primarily characterized by a constellation of motor symptoms such as bradykinesia, rigidity, postural instability and tremors. However, non-motor symptoms including gastrointestinal dysfunction, autonomic dysfunction and cognitive deficits are increasingly being accepted as part of the clinical manifestation of PD (Sveinbjornsdottir, 2016) . Pathologically, PD is characterized by the loss of dopamine neurons in the substantia nigra pars compacta (SNpc), the presence of Lewy bodies containing synuclein and the presence of activated glial cells, including microglia and astrocytes, accompanied by evidence of inflammation (Halliday and Stevens, 2011) .
Although the precise mechanisms leading to neurodegeneration are not known, increasing evidence points to a pivotal role for neuroinflammation in the initiation and progression of PD pathology (Collins et al., 2012; Wang et al., 2015) .
Recent studies have established that both central and peripheral inflammation occurs in PD (Su and Federoff, 2014) and that inflammatory signals promote a cytotoxic environment in the nigrostriatal pathway, which has a large microglial population (Barnum and Tansey, 2010; Ferrari et al., 2006 ). Experimental studies demonstrate that bacterial lipopolysaccharide (LPS) can induce and/or accelerate dopaminergic neurodegeneration in mice and rats (Dutta et al., 2008) . Both single and repeated dose LPS models have been used to study neurodegeneration of dopaminergic cells, in which LPS administration produces a prolonged state of neuroinflammation resulting in loss of dopamine neuron in days, weeks or months depending on the paradigm employed (Bodea et al., 2014; Cunningham et al., 2009; Liu and Bing, 2011; Qin et al., 2007) . Frank-Cannon and co-workers showed that parkin null mice treated with LPS exhibited loss of TH-immunoreactive cells by three Neurobiology of Disease 108 (2017) 115-127 
